Table 1.

Antimicrobial non-susceptibility among clinical S. pseudintermedius isolates from mid-2011 to the end of 2015 in Finland

Antimicrobial	MRSP			MSSP			All
	% non- susceptible	95% CI	number of isolates	% non- susceptible	95% CI	number of isolates	% non- susceptible	95% CI	number of isolates
Basic panel
clindamycina	85.7	80.8 –89.6	265	22.2	20.2 –24.3	1678	30.8	28.8 –32.9	1947
erythromycina	85.7	80.8 –89.6	266	21.8	19.9 –23.9	1678	30.5	28.5 –32.6	1949
fusidic acid	24.5	19.5 –30.2	265	24.3	22.3 –26.4	1677	24.4	22.5 –26.4	1946
oxacillina	100	98.2 –100	266	0	0.0 –0.3	1682	13.7	12.2 –15.3	1948
tetracyclinea	74	68.2 –79.1	265	33.3	31.1 –35.6	1675	38.8	36.6 –41.0	1944
trimethoprim/sulfamethoxazolea	47.7	41.6 –53.9	266	6.1	5.0 –7.4	1680	11.8	10.4 –13.3	1951
	MRSP			MSSP			All (2015)b
	% non- susceptible	95% CI	number of isolates	% non- susceptible	95% CI	number of isolates	% non- susceptible	95% CI	number of isolates
Extended panel
amikacin	0	0.0 –2.1	219	0	0.0 –0.9	547	0	0.0 –1.2	393
chloramphenicola	46.9	29.5 –65.0	32	15	10.6 –20.8	207	18.4	13.7 –24.2	228
doxycyclinea	28.8	18.6 –41.4	66	4.7	2.8 –7.7	342	6.1	4.0 –9.1	392
enrofloxacina	50.4	44.0 –56.8	248	2.6	1.7 –4.0	793	7.3	5.0 –10.4	395
gentamicina	44.8	38.5 –51.2	248	2.5	1.6 –3.9	795	6.6	4.4 –9.6	395

^aStatistically significant (P < 0.001) difference between MRSP and MSSP.

^bConsistent data only available for 2015, as the extended panel was only investigated for MRSP or otherwise MDR isolates prior to this.